← Back to screener

UNITED THERAPEUTICS Corp UTHR

Rank #622 · Nasdaq · $25.4B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
61.5
P/E
25.8
P/B
5.30
ROE
20.5%
Op. Margin
50.9%
Debt Ratio
19%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 25.8x, P/B 5.30x. Ranks in the top 51% of the universe.

Profitability ★★★★☆
Excellent

ROE 20.5%. Ranks in the top 12% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 19%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 20.2% year over year. Ranks in the top 18% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.4B$0.0B–$0.6B7.297
2012$0.6B$0.2B–$0.7B28.986
2013$0.7B$0.3B–$0.9B42.860
2014$0.9B$0.4B–$0.9B46.083
2015$1.1B$0.3B–$1.1B26.257
2016$1.3B$0.5B–$1.3B41.846
2017$1.5B$0.7B$0.7B$1.2B47.737
2018$1.6B$1.1B$0.7B$1.6B66.448
2019$1.7B$0.8B$0.4B$1.9B47.232
2020$1.6B$0.8B–$2.1B49.554
2021$1.4B$-0.2B–$2.8B-12.944
2022$1.5B$0.6B–$2.8B40.044
2023$1.7B$0.6B$0.5B$3.4B33.037
2024$1.9B$1.0B$0.7B$4.0B50.630
2025$2.3B$1.2B$1.0B$4.8B50.919

← See the full screener